FDA slams 23andMe over genetic testing device

Share this article:
23andMe makes its debut on TV
23andMe makes its debut on TV

Just three months after airing its first DTC campaign, the Google-backed genetics firm 23andMe received a warning letter from FDA saying it must discontinue marketing of its Personal Genome Service (PGS).

Concerns centered on the device's growing list of medical uses on the company website. Some of those uses, FDA said, have “not been classified and thus require premarket approval.” The agency said marketing must be discontinued until the device has been properly tested.

In the letter, regulators said some of those intended uses, like “assessment for BRCA-related genetic risk and drug responses,” were “particularly concerning,” due to the chance of false-negatives and false-positives, which could lead to unnecessary treatment or a missed diagnosis. 

PGS, as described on 23andMe's website, uses customers' DNA to provide "specific health recommendations" and "learn about and explore their DNA."

In an e-mailed statement to MM&M, 23andMe confirmed receipt of the directive.

"We have received the warning letter from the Food and Drug Administration," the firm noted, adding, "We recognize that we have not met the FDA's expectations regarding timeline and communication regarding our submission. Our relationship with the FDA is extremely important to us and we are fully committed to fully engaging with them to address their concerns."

The agency said 23andMe "initiated new marketing campaigns, including television commercials that, together with an increased list of indications, show that you plan to expand the PGS's uses and consumer base without obtaining proper marketing authorization from FDA." 

23andMe submitted a 510(k) medical device clearance for PGS in 2012, but "failed to address issues described during previous interactions for use," said Alberto Gutierrez, Director of FDA's Center for Devices and Radiological Health.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...